[Effects of mangesium salts and their combinations with vitamin B6 on oxalates crystalluria in rats fed with pyridoxine-deficient diet].
We studied the effects of oral magnesium (Mg) salts either alone or in combination with pyridoxine hydrochloride in rats on pyridoxine-deficient diet. Fifty-four male rats were randomized into two groups and were fed either a standard diet or a pyridoxine-deficient diet for 3 weeks. A significant rise of the EGOT index ( > 1.5), oxaluria (from 74.8 +/- 5.2 to 117.9 +/- 12.3 mcM/l, p = 0.035), and crystalluria in rats fed with pyridoxine deficient diet were revealed. Oral Mg chloride, Mg L-aspartate either alone or in combination with pyridoxine in comparison with magnesium sulfate, magne B6 (Mg lactate with pyridoxine) and pyridoxine alone were administered (50 mg of magnesium and/or 5 mg of pyridoxine per kg body weight). Magnesium salts in combination with pyridoxine lowered an oxalate level and crystalluria whereas magnesium salts alone reduced only crystalluria. Antilithis effects of Mg L-aspartate and Mg chloride in combination with pyridoxine were comparable with those observed in magne B6 or pyridoxine treatment and were significantly higher than in magnesium sulfate treatment.
Spasov
A A
AA
Iezhitsa
I N
IN
Kharitonova
M V
MV
Kravchenko
M S
MS
D000818:Animals; D001219:Aspartate Aminotransferases / Q000378:metabolism; D001224:Aspartic Acid / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use; D003460:Crystallization; D004032:Diet; D004195:Disease Models, Animal; D004359:Drug Therapy, Combination; D004912:Erythrocytes / Q000201:enzymology; D006959:Hyperoxaluria / Q000097:blood / Q000209:etiology / Q000517:prevention & control* / Q000652:urine; D008274:Magnesium / Q000097:blood / Q000652:urine; D015636:Magnesium Chloride / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use; D017616:Magnesium Compounds / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D008278:Magnesium Sulfate / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use; D008297:Male; D010070:Oxalates / Q000652:urine*; D011736:Pyridoxine / Q000008:administration & dosage / Q000172:deficiency / Q000627:therapeutic use*; D051381:Rats; D016896:Treatment Outcome
D017616:Magnesium Compounds; D010070:Oxalates; D015636:Magnesium Chloride; D001224:Aspartic Acid; D008278:Magnesium Sulfate; D001219:Aspartate Aminotransferases; D008274:Magnesium; D011736:Pyridoxine